Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)
Mothe, Beatriz (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Manzardo, Christian (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Sánchez-Bernabeu, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Coll, Pep (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Moron-Lopez, Sara (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Puertas, Maria C. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Rosás-Umbert, Miriam (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Cobarsi, Patricia (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Escrig, Roser (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Pérez-Álvarez, Núria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Ruiz, Irene (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Rovira, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Meulbroek, Michael (Projecte del Noms, BCN Checkpoint, Barcelona, Spain)
Crook, Alison (The Jenner Institute, University of Oxford, Oxford, UK)
Borthwick, Nicola (The Jenner Institute, University of Oxford, Oxford, UK)
Wee, Edmund G. (The Jenner Institute, University of Oxford, Oxford, UK)
Yang, Hongbing (University of Oxford. Nuffield Department of Medicine)
Miró, José M (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Dorrell, Lucy (University of Oxford. Nuffield Department of Medicine)
Pérez-Álvarez, Núria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Martínez Picado, Francisco Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Brander, Christian (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Hanke, Tomáš (International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan)
Universitat Autònoma de Barcelona

Data:	2019
Resum:	Strong and broad antiviral T-cell responses targeting vulnerable sites of HIV-1 will likely be a critical component for any effective cure strategy. BCN01 trial was a phase I, open-label, non-randomized, multicenter study in HIV-1-positive individuals diagnosed and treated during early HIV-1 infection to evaluate two vaccination regimen arms, which differed in the time (8 versus 24 week) between the ChAdV63. HIVconsv prime and MVA. HIVconsv boost vaccinations. The primary outcome was safety. Secondary endpoints included frequencies of vaccine-induced IFN-γ + CD8 + T cells, in vitro virus-inhibitory capacity, plasma HIV-1 RNA and total CD4 + T-cells associated HIV-1 DNA. (). No differences in safety, peak magnitude or durability of vaccine-induced responses were observed between long and short interval vaccination arms. Grade 1/2 local and systemic post-vaccination events occurred in 22/24 individuals and resolved within 3 days. Weak responses to conserved HIV-1 regions were detected in 50% of the individuals before cART initiation, representing median of less than 10% of their total HIV-1-specific T cells. All participants significantly elevated these subdominant T-cell responses, which after MVA. HIVconsv peaked at median (range) of 938 (73-6,805) IFN-γ SFU/10 6 PBMC, representing on average 58% of their total anti-HIV-1 T cells. The decay in the size of the HIV-1 reservoir was consistent with the first year of early cART initiation in both arms. Heterologous prime-boost vaccination with ChAdV63-MVA/HIVconsv was well-tolerated and refocused pre-cART T-cell responses towards more protective epitopes, in which immune escape is frequently associated with reduced HIV-1 replicative fitness and which are common to most global HIV-1 variants. HIVACAT Catalan research program for an HIV vaccine and Fundació Gloria Soler. Vaccine manufacture was jointly funded by the Medical Research Council (MRC) UK and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreements (G0701669. Evidence Before this Study: T cells play an important role in the control of HIV infection and may be particularly useful for HIV-1 cure by killing cells with reactivated HIV-1. Evidence is emerging that not all T-cell responses are protective and mainly only those targeting conserved regions of HIV-1 proteins are effective, but typically immunologically subdominant, while those recognizing hypervariable, easy-to-escape immunodominant 'decoys' do not control viremia and do not protect from a loss of CD4 T cells. We pioneered a vaccine strategy focusing T-cell responses on the most conserved regions of the HIV-1 proteome using an immunogen designated HIVconsv. T cells elicited by the HIVconsv vaccines in HIV-uninfected UK and Kenyan adults inhibited in vitro replication of HIV-1 isolates from 4 major global clades A, B, C and D. Added Value of this Study: The present study demonstrated the concept that epitopes subdominant in natural infection, when taken out of the context of the whole HIV-1 proteome and presented to the immune system by a potent simian adenovirus prime-poxvirus MVA boost regimen, can induce strong responses in patients on antiretroviral treatment and efficiently refocus HIV-1-specific T-cells to the protective epitopes delivered by the vaccine. Implications of all the Available Evidence: Nearly all HIV-1 vaccine strategies currently emphasize induction of broadly neutralizing Abs. The HIVconsv vaccine is one of a very few approaches focussing exclusively on elicitation of T cells and, therefore, can complement antibody induction for better prevention and cure. Given the cross-clade reach on the HIVconsv immunogen design, if efficient, the HIVconsv vaccines could be deployed globally. Effective vaccines will likely be a necessary component in combination with other available preventive measures for halting the HIV-1/AIDS epidemic.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	EClinicalMedicine, Vol. 11 (june 2019) , p. 65-80, ISSN 2589-5370

DOI: 10.1016/j.eclinm.2019.05.009
PMID: 31312806

16 p, 2.9 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats